参芪扶正注射液对急性淋巴细胞白血病化疗患者造血和免疫功能的影响

目的:观察参芪扶正注射液对急性淋巴细胞白血病化疗患者造血及免疫功能的影响。方法:收集96例处于初治诱导缓解治疗阶段的急性淋巴细胞白血病患者,并将其随机分为治疗组和对照组。治疗组48例患者在进行常规化疗的同时给予参芪扶正注射液250 m L,1次/天,共28天;对照组48例患者仅接受常规化疗,两组患者均给予相同的支持对症治疗。治疗结束后,观察两组患者的疾病缓解率、治疗前后造血系统、T和B淋巴细胞亚群的变化情况。结果:化疗结束后,治疗组患者的疾病缓解率为89.6%,对照组为83.3%,两组比较无统计学差异(P0.05);化疗14天及化疗结束后1周,治疗组患者的白细胞、红细胞计数和血红蛋白水平明显高于对照组(P0.05);且化疗结束后1周,治疗组患者的CD3+、CD4+及CD4+/CD8+含量均明显高于对照组(P0.05)。而两组患者治疗前后的血小板计数、CD3-CD19+含量比较均不具有统计学差异(P0.05)。结论:参芪扶正注射液辅助治疗不仅能够改善化疗所致的急性淋巴细胞白血病患者的骨髓抑制,而且能够提高其细胞免疫功能,有助于患者化疗后的恢复。

The Effects of Shenqi Fuzheng Injection on Hematopoietic and Immune Function of Acute Lymphoblastic Leukemia Patients with Chemotherapy

Objective:To investigate the effects of Shenqi Fuzheng Injection (SFI) on hematopoietic and immunologic function of acute lymphoblastic leukemia (ALL) patients with chemotherapy.Methods:Ninety-six ALL patients in the early stages of treatment to induce remission were randomly divided into two groups: forty-eight patients of treatment group were treated by chemotherapy with SFI 250 mL, once per day, 28 days; while the other forty-eight patients of control group were just treated by chemotherapy. Both groups were given the same symptomatic and supportive treatment. After treatment, the disease remission rate (DFR), changes of the hematopoietic system, T and B lymphocyte subsets before and after treatment were observed and compared between the two groups.Results:After treatment, the DFR of the two groups showed no significant difference (89.6% vs 83.3%, P>0.05). On the 1 4th day during chemotherapy and 7th after chemotherapy, the counts of white blood cells and red blood cells as well as hemoglobin level of the treatment group were all significantly higher than those of the control group (P<0.05). Moreover, on the 7th day after chemotherapy, the CD3+, CD4+ and CD4+/ CD8+ count of the treatment group were both significantly higher than those of the control group (P<0.05), but no significant difference was observed between the two groups in the CD3-CD19+ count (P>0.05).Conclusion:SFI could not only relieve the chemotherapy induced myelosuppression of ALL patients, but also enhance the immunologic function and contribute to the recovery after chemotherapy.